Metabolic Syndrome, Central Obesity and Insulin Resistance are Associated with Adverse Pathological Features in Postmenopausal Breast Cancer

被引:119
|
作者
Healy, L. A. [1 ,2 ]
Ryan, A. M. [1 ,2 ]
Carroll, P. [2 ,3 ]
Ennis, D. [2 ,3 ]
Crowley, V. [2 ,4 ]
Boyle, T. [2 ,3 ]
Kennedy, M. J. [2 ,5 ]
Connolly, E. [2 ,3 ]
Reynolds, J. V. [2 ,3 ]
机构
[1] St James Hosp, Dept Clin Nutr, Dublin 8, Ireland
[2] Univ Dublin Trinity Coll, Dublin 2, Ireland
[3] St James Hosp, Dept Surg, Dublin 8, Ireland
[4] St James Hosp, Dept Clin Chem, Dublin 8, Ireland
[5] St James Hosp, Acad Unit Clin & Med Oncol, Dublin 8, Ireland
关键词
Breast cancer; metabolic syndrome; obesity; postmenopausal; tumour pathology; BODY-MASS INDEX; RECEPTOR EXPRESSION; SEX-HORMONES; RISK-FACTOR; C-PEPTIDE; WOMEN; SIZE; POPULATION; PREVALENCE; MORTALITY;
D O I
10.1016/j.clon.2010.02.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: Obesity is associated with both an increased risk of postmenopausal breast cancer and increased mortality rates. The mechanism is unclear, and central (visceral) obesity, insulin resistance, altered sex steroids and altered adipokines are mooted as possible factors. These features may cluster in the so-called metabolic syndrome. The relevance of metabolic syndrome to the biology of breast cancer is unknown, and this was the focus of the present study. Materials and methods: All postmenopausal women with newly diagnosed breast cancer (n = 105) were recruited. A detailed clinical history was carried out, as well as a body composition analysis, metabolic screen and measurement of adipokines and inflammatory markers. Results: The median age was 68 years (40-94 years) and the mean body mass index was 28.3 +/- 5.2 kg/m(2), with 87% of patients centrally obese. Metabolic syndrome was diagnosed in 39% of patients, and was significantly associated with central obesity (P < 0.005) and increased inflammation, with C-reactive protein levels doubling in metabolic syndrome patients compared with non-metabolic syndrome patients (10.3 vs 5.8 mg/l; P = 0.084). Patients with a later pathological stage (II-IV) were significantly more likely to be obese (P = 0.007), centrally obese (P = 0.009), hyperglycaemic (P = 0.047) and hyperinsulinaemic (P = 0.026); 51% had metabolic syndrome compared with 12% for early stage disease. Patients with node-positive disease were significantly more likely to be hyperinsulaemic (P = 0.030) and have metabolic syndrome (P = 0.028) than patients with node-negative disease. Discussion: The data suggest that metabolic syndrome and central obesity are common in postmenopausal breast cancer patients, and that metabolic syndrome may be associated with a more aggressive tumour biology. (C) 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:281 / 288
页数:8
相关论文
共 50 条
  • [31] Metabolic Obesity Phenotypes and Risk of Breast Cancer in Postmenopausal Women
    Kabat, Geoffrey C.
    Kim, Mimi Y.
    Lee, Jennifer S.
    Ho, Gloria Y.
    Going, Scott B.
    Beebe-Dimmer, Jennifer
    Manson, Joann E.
    Chlebowski, Rowan T.
    Rohan, Thomas E.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2017, 26 (12) : 1730 - 1735
  • [32] Peripheral neuropathy is associated with insulin resistance independent of metabolic syndrome
    Han, Ling
    Ji, Lijin
    Chang, Jing
    Wen, Jian
    Zhao, Wenting
    Shi, Hongli
    Zhou, Linuo
    Li, Yiming
    Hu, Renming
    Hu, Ji
    Lu, Bin
    DIABETOLOGY & METABOLIC SYNDROME, 2015, 7
  • [33] Risk of metabolic syndrome in postmenopausal breast cancer survivors
    Brito Buttros, Daniel de Araujo
    Petri Nahas, Eliana Aguiar
    Vespoli, Heloisa De Luca
    Uemura, Gilberto
    de Almeida, Bruno da Rosa
    Nahas-Neto, Jorge
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2013, 20 (04): : 448 - 454
  • [34] Symposium 3: Obesity-related cancers Visceral obesity, metabolic syndrome, insulin resistance and cancer
    Doyle, Suzanne L.
    Donohoe, Claire L.
    Lysaght, Joanne
    Reynolds, John V.
    PROCEEDINGS OF THE NUTRITION SOCIETY, 2012, 71 (01) : 181 - 189
  • [35] Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: A nested case-control study
    Agnoli, C.
    Berrino, F.
    Abagnato, C. A.
    Muti, P.
    Panico, S.
    Crosignani, P.
    Krogh, V.
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2010, 20 (01) : 41 - 48
  • [36] Association between sarcopenic obesity with insulin resistance and metabolic syndrome
    Perez-Cruz, Elizabeth
    Castro-Martinez, Daniela
    Pavel Gonzalez-Guzman, Otto
    MEDICINA CLINICA, 2022, 159 (01): : 1 - 5
  • [37] Metabolic syndrome affects breast-cancer risk in postmenopausal women National Cancer Institute of Naples experience
    Capasso, Immacolata
    Esposito, Emanuela
    Pentimalli, Francesca
    Crispo, Anna
    Montella, Maurizio
    Grimaldi, Maria
    De Marco, MariaRosaria
    Cavalcanti, Ernestina
    D'Aiuto, Massimiliano
    Fucito, Alfredo
    Frasci, Giuseppe
    Maurea, Nicola
    Esposito, Giuseppe
    Pedicini, Tonino
    Vecchione, Aldo
    D'Aiuto, Giuseppe
    Giordano, Antonio
    CANCER BIOLOGY & THERAPY, 2010, 10 (12) : 1240 - 1243
  • [38] Evaluation of metabolic syndrome, insulin secretion and insulin resistance in adolescents with overweight and obesity
    Vityala, Yethindra
    Tagaev, Tugolbai
    Zhumabekova, Altynai
    Mamatov, Sagynali
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2022, 128 : S19 - S19
  • [39] Hypertension is the primary component of metabolic syndrome associated with pathologic features of kidney cancer
    Kocher, Neil J.
    Rjepaj, Chris
    Robyak, Haley
    Lehman, Erik
    Raman, Jay D.
    WORLD JOURNAL OF UROLOGY, 2017, 35 (01) : 67 - 72
  • [40] The Metabolic Syndrome-from Insulin Resistance to Obesity and Diabetes
    Gallagher, Emily Jane
    LeRoith, Derek
    Karnieli, Eddy
    MEDICAL CLINICS OF NORTH AMERICA, 2011, 95 (05) : 855 - +